Home Healthcare Healthcare Services Oligonucleotide CDMO Market

Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Service Type (Contract Manufacturing, Contract Development), By Type (Antisense Oligonucleotides, Small Interfering RNA, Other Oligonucleotides), By Application (Therapeutic, Research, Diagnostic), By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostic Companies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 24, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Oligonucleotide CDMO Market, By Service Type 2022-2034 (USD MILLION/ Units)
    1. Contract Manufacturing
    2. Contract Development
  2. Oligonucleotide CDMO Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Antisense Oligonucleotides
    2. Small Interfering RNA
    3. Other Oligonucleotides
  3. Oligonucleotide CDMO Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Therapeutic
    2. Research
    3. Diagnostic
  4. Oligonucleotide CDMO Market, By End Use 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical and Biopharmaceutical Companies
    2. Diagnostic Companies
    3. Others
  5. Regional Oligonucleotide CDMO Market
    1. North America
      1. North America Oligonucleotide CDMO Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Contract Manufacturing
        2. Contract Development
      2. North America Oligonucleotide CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Antisense Oligonucleotides
        2. Small Interfering RNA
        3. Other Oligonucleotides
      3. North America Oligonucleotide CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Therapeutic
        2. Research
        3. Diagnostic
      4. North America Oligonucleotide CDMO Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Diagnostic Companies
        3. Others
      5. U.S.
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      6. Canada
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
    2. Europe
      1. Europe Oligonucleotide CDMO Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Contract Manufacturing
        2. Contract Development
      2. Europe Oligonucleotide CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Antisense Oligonucleotides
        2. Small Interfering RNA
        3. Other Oligonucleotides
      3. Europe Oligonucleotide CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Therapeutic
        2. Research
        3. Diagnostic
      4. Europe Oligonucleotide CDMO Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Diagnostic Companies
        3. Others
      5. U.K.
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      6. Germany
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      7. France
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      8. Spain
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      9. Italy
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      10. Russia
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      11. Nordic
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      12. Benelux
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      13. Rest of Europe
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
    3. APAC
      1. APAC Oligonucleotide CDMO Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Contract Manufacturing
        2. Contract Development
      2. APAC Oligonucleotide CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Antisense Oligonucleotides
        2. Small Interfering RNA
        3. Other Oligonucleotides
      3. APAC Oligonucleotide CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Therapeutic
        2. Research
        3. Diagnostic
      4. APAC Oligonucleotide CDMO Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Diagnostic Companies
        3. Others
      5. China
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      6. Korea
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      7. Japan
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      8. India
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      9. Australia
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      10. Taiwan
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      11. South East Asia
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      12. Rest of Asia-Pacific
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
    4. Middle East and Africa
      1. Middle East and Africa Oligonucleotide CDMO Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Contract Manufacturing
        2. Contract Development
      2. Middle East and Africa Oligonucleotide CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Antisense Oligonucleotides
        2. Small Interfering RNA
        3. Other Oligonucleotides
      3. Middle East and Africa Oligonucleotide CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Therapeutic
        2. Research
        3. Diagnostic
      4. Middle East and Africa Oligonucleotide CDMO Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Diagnostic Companies
        3. Others
      5. UAE
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      6. Turkey
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      7. Saudi Arabia
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      8. South Africa
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      9. Egypt
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      10. Nigeria
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      11. Rest of MEA
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
    5. LATAM
      1. LATAM Oligonucleotide CDMO Market By Service Type 2022-2034 (USD MILLION/ Units)
        1. Contract Manufacturing
        2. Contract Development
      2. LATAM Oligonucleotide CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Antisense Oligonucleotides
        2. Small Interfering RNA
        3. Other Oligonucleotides
      3. LATAM Oligonucleotide CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Therapeutic
        2. Research
        3. Diagnostic
      4. LATAM Oligonucleotide CDMO Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical and Biopharmaceutical Companies
        2. Diagnostic Companies
        3. Others
      5. Brazil
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      6. Mexico
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      7. Argentina
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      8. Chile
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      9. Colombia
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
      10. Rest of LATAM
        1. Contract Manufacturing
        2. Contract Development
        3. Antisense Oligonucleotides
        4. Small Interfering RNA
        5. Other Oligonucleotides
        6. Therapeutic
        7. Research
        8. Diagnostic
        9. Pharmaceutical and Biopharmaceutical Companies
        10. Diagnostic Companies
        11. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.